令和7年度

巻頭言

2025年度
ライフサイエンス研究所紀要発刊によせて
研究所長
永井　義隆

　近畿大学ライフサイエンス研究所は、1974 年に大阪狭山キャンパスに設立されて以
来、生命現象の科学的解明と人類の健康及び福祉の増進に貢献してまいりました。近年
は、先進的な分析技術、特にゲノムの網羅的解析を基盤とした個別化医療とプレシジョ
ン医療を推進しております。2022 年には、人口高齢化に伴って患者数が増加している
難治性神経疾患の研究を担う新たな研究室を設置し、革新的な診断法・治療法開発を目
指した研究を展開しております。また、研究成果の社会実装に向けて、複数の共同研究
プロジェクトを積極的に展開し、連携を強化してまいりました。そして、2025 年11 月
に医学部、近畿大学病院と共におおさかメディカルキャンパスへ移転し、新たな拠点に
て活動を開始しました。
　本研究所では、医師の働き方改革や研究資源の効率的な活用が求められる中、医学部
のみならず他学部との交流を促進し、持続可能な研究環境を支援するなど、多角的な視
点から生命現象の解明に取り組んでいます。2025 年度は新キャンパスへの移転準備な
ど一時的な研究活動の中断があったにもかかわらず、基礎・臨床の両面で、数多くの質
の高い研究成果が発表されました。これは、日々研究に取り組む研究者および技術職員
の皆さんの弛まぬ努力の賜物であり、心より敬意を表します。
　今後も、ライフサイエンス研究所では、所員一同が協力し、生命科学の進展と社会へ
の貢献に向けて努力を続けていく所存です。当研究所の研究活動を支えてくださる全て
の関係者の皆様に、心より感謝申し上げます。

令和7年度ライフサイエンス研究所紀要研究業績

永井義隆（ライフサイエンス研究所副所長
兼任近畿大学医学部内科学教室〔脳神経内科部門〕主任教授）

Hasumi M, Ito H, Machida K, Niwa T, Taminato T, Nagai Y, Imataka H, Taguchi H. Dissecting
the mechanism of NOP56 GGCCUG repeat-associated non-AUG translation using cell-free
translation systems.J.Biol Chem. 301(4): 108360 (2025) doi: 10.1016/j.jbc.2025.108360
Aguirre C, Miyanoiri Y, So M, Tamaki H, Maruno T, Doi J, Wang N, Yamaguchi K, Nakajima K,
Yamamori Y, Inoura H, Choong C.J, Kakuda K, Ajiki T, Kimura Y, Ozono T, Baba K, Nagano S,
Nagai Y, Ogi H, Uchiyama S, Matsuki Y, Tomii K, Goto Y, Ikenaka K, Mochizuki H.
Conformational switch in the alpha-synuclein C-terminus domain directs its fibril polymorphs.
Chemistry 31(37): e202500650 (2025) doi: 10.1002/chem.202500650
Hirano M, Samukawa M, Isono C, Inada R, Fukumoto Y, Yoshikawa K, Namura H, Sakata H,
Hisatomi T, Michiura T, Nakamura H, Morita A, Hoshino G, Yamana K, Terayama A,
Higashimoto Y, Mitsui Y, Nagai Y. Effects of the continuous subcutaneous infusion of
foslevodopa-foscarbidopa on swallowing in patients with Parkinson's disease. Clin.
Parkinsonism Relat. Disord. 13:100378 (2025) doi: 10.1016/j.prdoa.2025.100378
Hirano M, Samukawa M, Miyatake S, Yamagishi Y, Isono C, Yoshikawa R, Saigoh K, Terayama
A, Higashimoto Y, Koshimizu E, Mizuguchi T, Fujii K, Mitsui Y, Matsumoto N, Nagai Y. Noncoding
repeat analyses in patients with Parkinson's disease. Front. Neurol. 16:1606305 (2025)
doi: 10.3389/fneur.2025.1606305
Tashiro T, Ogata H, Kuwahara M, Nishijima H, Nogami K, Yamaguchi T, Hayashida H,
Maimaitijiang G, Yamasaki R, Kira J, Nagai Y, Isobe N. Anti-contactin-1 autoimmune nodopathy
with thymoma: case report and literature review. Front. Immunol. 16:1662299 (2025) doi:
10.3389/fimmu.2025.1662299
Ito H, Machida K, Fujino Y, Hasumi M, Sakamoto S, Nagai Y, Imataka H, Taguchi H. Canonical
translation factors eIF1A and eIF5B modulate the initiation step of repeat-associated non-AUG
translation. Nucleic Acids Res. 53(18): gkaf994 (2025) doi: 10.1093/nar/gkaf994
Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M,
Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito
Y, Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset model with
germline transmission that models polyglutamine disease. Dis. Model. Mech. 18(10):
dmm052470 doi:10.1242/dmm.052470
Fujii K, Takeuchi T, Fujino Y, Tanaka N, Fujino N, Takeda A, Minakawa EN, Nagai Y. Oral
administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease.
Neurochem. Int. 191: 106082 (2025) doi: 10.1016/j.neuint.2025.106082
Mori T, Iwawaki N, Shigi K, Takehara T, Takenaka S, Nagai Y, Teramura T. Mesenchymal stromal
cells preserve alveolar macrophages by inducing Sesn2 expression via lactic acid production in a
mouse model of bleomycin-induced lung injury. Cell Transplant. 34: 1-16 (2025) doi:
10.1177/09636897251397044
Kimura Y, Koda T, Kurakami H, Sakamoto S, Iwasaki K, Asai K, Ge L, Kato H, Tsuboi T,
Matsukawa N, Osamu K, Matsuse D, Tomiyama M, Yokoe M, Nagai Y, Mochizuki H. Diseasemodifying
effect, safety, and optimal dose of oral semaglutide tablets for patients with Parkinson's
disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo- controlled study.
BMJ Open 15: e112318 (2025) doi:10.1136/bmjopen-2025-112318
Takeda A, Takeuchi T, Minakawa EN, Tanaka N, Mochizuki H, Nagai Y. Blood extracellular
vesicles contribute to the exercise-mediated suppression of brain Aβ pathology in the AppNL-GF
knockin mouse model of Alzheimer's disease. Neurochem. Int. 193: 106120 (2026) doi:
10.1016/j.neuint.2026.106120

重吉康史（ライフサイエンス研究所教授兼任近畿大学医学部解剖学教室主任教授）

Kawabe J, Kawakami N, Hirose M, Kitamura Y, Nagano M, Maruyama Y,Matsuyama Y,
Hamano T, Koinuma S, Shiina T, Kobayashi M, Matsumura R, HattoriA, Shigeyoshi Y, Ogura
A, Node K, Akashi M. Targeted disruption of the aralkylamine N-acetyltransferasegene in a
seasonal mammal, Mesocricetus auratus. PNAS Nexus. 2025 Jun;4(6).
doi:10.1093/pnasnexus/pgaf159.
Kanazawa Y, Miyahara K, Takahashi T, Miyachi R, Nagano M, Koinuma S, Iida N, Inoue T,
Shigeyoshi Y. Aging Impairs Intramuscular Collagen Remodeling Responses to Repeated Passive
Stretching in Skeletal Muscle. International journal of Molecular Sciences. 2026 Mar
18;27(6):2753. doi:10.3390/ijms27062753.

西尾和人（ライフサイエンス研究所ゲノムセンター長教授
兼任近畿大学医学部ゲノム生物学教室主任教授）

Fujita Y, De Velasco MA, Hayashi H, Nakagawa K, Nishio K. Exploration of genes related to the
development of cancer of unknown primary. Oncol Rep. 2025 Jun;53(6):72. doi:
10.3892/or.2025.8905. Epub 2025 May 2.
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K,
Hayashi H, Sakai K, Enatsu S, Frimodt-Møller B, Matsui T, Varughese SC, Carlsen M, Visseren-
Grul C, Nakagawa K. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo
Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese
Subset. JTO Clin Res Rep. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819.
eCollection 2025 Jun.
Adomi S, Sakai K, Kura Y, De Velasco MA, Fujimoto S, Toyoda S, Hashimoto M, Nishimoto M,
Banno E, Saito Y, Sugimoto K, Hayashi Y, Minami T, Yoshimura K, Uemura H, Nishio K, Fujita
K. Comparison of genetic mutations in bladder cancers that arose following radiotherapy for
prostate cancer with those in primary bladder cancers. Sci Rep. 2025 Jul 1;15(1):20495. doi:
10.1038/s41598-025-05149-z.
Ohta M, Murakami K, Otani T, Sakai K, Nishio K, Matsumura N. Synchronous endometrial and
ovarian cancers originating from distinct clonal lineages in Lynch syndrome: A case report and
review of the literature. J Obstet Gynaecol Res. 2025 Jul;51(7):e70003. doi: 10.1111/jog.70003.
Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, Tanizaki J, Suzuki S, Tomida
S, Sakai K, Chiba Y, Ito A, Nishio K, Nakagawa K, Hayashi H. Impact of B7-H3 and DLL3
expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Lung Cancer. 2025 Sep;207:108723. doi: 10.1016/j.lungcan.2025.108723. Epub 2025 Aug 23.
Oiki H, Suda K, Hamada A, Fujino T, Obata K, Kobayashi Y, Sakai K, Fukuda S, Ohara S, Ito
M, Soh J, Nishio K, Mitsudomi T, Tsutani Y. Efficacy of Conventional and Novel Tyrosine Kinase
Inhibitors for Uncommon EGFR Mutations-An In Vitro Study. Cells. 2025 Sep 4;14(17):1386.
doi: 10.3390/cells14171386.
Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, Azuma K, Asahina H,
Kisohara A, Kawashima Y, Tanaka H, Kanemaru R, Miyauchi E, Furuya N, Sato H, Nakashima
K, Watanabe S, Sakai K, Nishio K, Takahashi F, Kobayashi K, Maemondo M. A phase II study
of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutationpositive
non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line
osimertinib treatment: NEJ025B study. Eur J Cancer. 2025 Oct 16;229:115693. doi:
10.1016/j.ejca.2025.115693. Epub 2025 Aug 20.
Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K,
Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K,
Yamamoto N, Ohe Y, Okamoto I. Biological impact of chemotherapy during treatment with
EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating
mutations. Lung Cancer. 2025 Oct;208:108756. doi: 10.1016/j.lungcan.2025.108756. Epub 2025
Sep 16.
Nishino K, Seto T, Nishio M, Nishio K, Kasahara K, Satouchi M, Yoh K, Hayashi H, Enatsu S,
Matsui T, Varughese SC, Visseren-Grul C, Nakagawa K. RELAY: safety and efficacy of
ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
Future Oncol. 2025 Oct;21(24):3197-3206. doi: 10.1080/14796694.2025.2560225. Epub 2025
Sep 25.
Saito Y, Adomi S, Sakai K, Antonio De Velasco M, Hashimoto M, Banno E, Hayashi Y, Minami
T, Nishio K, Fujita K. Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter
Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Nonmuscle-
Invasive Bladder Cancer. Cureus. 2025 Aug 24;17(8):e90860. doi: 10.7759/cureus.90860.
eCollection 2025 Aug.
Kawanaka Y, Yonesaka K, Tanizaki J, Maenishi O, Sakai K, Kakimi K, Nishio K, Hayashi H.
Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma
demonstrated a long-term remission to anti PD-1 antibody. Front Oncol. 2025 Sep 10;15:1651248.
doi: 10.3389/fonc.2025.1651248. eCollection 2025.
Sumitomo M, Kotani Y, Murakami K, Abiko K, Sakai K, Otani T, Ueda A, Ukita M, Taga A,
Emoto I, Sekiyama K, Okudate M, Matsubara M, Yamanishi Y, Nishio K, Mandai M, Matsumura
N. Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study. Cancers (Basel). 2025
Sep 19;17(18):3069. doi: 10.3390/cancers17183069.
Kajiyama H, Kashima Y, Otani T, Sakai K, Shiraishi N, Nishio K, Shishido-Hara Y, Ito A,
Minamiguchi S, Matsumura N. Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-
Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation.
Int J Gynecol Pathol. 2025 Oct 2. doi: 10.1097/PGP.0000000000001142. Online ahead of print.
Kurosaki T, Suzuki S, Yonesaka K, Kawanaka Y, Takehara T, Teramura T, Sakai K, Nishio K,
Hayashi H. Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer
Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. Int J
Mol Sci. 2025 Oct 29;26(21):10515. doi: 10.3390/ijms262110515.
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K,
Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa
K. RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With
Untreated EGFR-Mutated Metastatic NSCLC. JTO Clin Res Rep. 2025 Sep 26;6(12):100912.
doi: 10.1016/j.jtocrr.2025.100912. eCollection 2025 Dec.
Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T,
Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E,
Nishio K, Matsumura N. Long-term progression-free survivors ("super responders") to olaparib
maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s). Int J
Clin Oncol. 2026 Feb;31(2):310-318. doi: 10.1007/s10147-025-02942-8. Epub 2025 Dec 22.
Kashima Y, Takaya H, Miyagawa C, Otani T, Sakai K, Nishio K, Matsumura N. A case of
endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma
as a result of TMEM178B-BRAF fusion. Int Cancer Conf J. 2025 Nov 8;15(1):99-102. doi:
10.1007/s13691-025-00823-5. eCollection 2026 Jan.
Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I,
Nishio K. Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse
Large B-Cell Lymphoma. Cancer Med. 2026 Feb;15(2):e71597. doi: 10.1002/cam4.71597.
Iwahashi N, Noguchi T, Sakai K, Yahata T, Nishioka K, Fujino M, Takeda S, Suzuki N, Nishio
K, Ino K. Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy
for cervical cancer. Int J Clin Oncol. 2026 Mar 10. doi: 10.1007/s10147-026-03006-1. Online
ahead of print.
Isomoto K, Haratani K, Tsujikawa T, Tomida S, Makutani Y, Takeda M, Yonesaka K, Tanaka K,
Iwasa T, Sakai K, Nishio K, Ito A, Nakagawa K, Hayashi H. Spatial single-cell proteotyping
reveals immunotherapy-resistant features within the complex tumor microenvironment of
metastatic NSCLC. J Clin Invest. 2026 Mar 10:e195021. doi: 10.1172/JCI195021. Online ahead
of print.
Kanemura H, Takehara T, Maenishi O, Tomida S, Iwawaki N, Kunimasa K, Nakayama T,
Watanabe S, Suzuki S, Sakai K, Azuma K, Kudo K, Nishio K, Nakagawa K, Hayashi H, Teramura
T, Yonesaka K. Constitutive EGFR Activation Induced by PTPRR Downregulation Confers
Resistance to KRAS Inhibitors. Cancer Res Commun. 2026 Apr 1;6(4):728-741. doi:
10.1158/2767-9764.CRC-25-0489.

坂井和子（ライフサイエンス研究所ゲノムセンター准教授
兼任近畿大学医学部ゲノム生物学教室准教授）

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K,
Hayashi H, Sakai K, Enatsu S, Frimodt-Møller B, Matsui T, Varughese SC, Carlsen M, Visseren-
Grul C, Nakagawa K. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo
Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese
Subset. JTO Clin Res Rep. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819.
eCollection 2025 Jun.
Adomi S, Sakai K, Kura Y, De Velasco MA, Fujimoto S, Toyoda S, Hashimoto M, Nishimoto M,
Banno E, Saito Y, Sugimoto K, Hayashi Y, Minami T, Yoshimura K, Uemura H, Nishio K, Fujita
K. Comparison of genetic mutations in bladder cancers that arose following radiotherapy for
prostate cancer with those in primary bladder cancers. Sci Rep. 2025 Jul 1;15(1):20495. doi:
10.1038/s41598-025-05149-z.
Ohta M, Murakami K, Otani T, Sakai K, Nishio K, Matsumura N. Synchronous endometrial and
ovarian cancers originating from distinct clonal lineages in Lynch syndrome: A case report and
review of the literature. J Obstet Gynaecol Res. 2025 Jul;51(7):e70003. doi: 10.1111/jog.70003.
Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, Tanizaki J, Suzuki S, Tomida
S, Sakai K, Chiba Y, Ito A, Nishio K, Nakagawa K, Hayashi H. Impact of B7-H3 and DLL3
expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Lung Cancer. 2025 Sep;207:108723. doi: 10.1016/j.lungcan.2025.108723. Epub 2025 Aug 23.
Oiki H, Suda K, Hamada A, Fujino T, Obata K, Kobayashi Y, Sakai K, Fukuda S, Ohara S, Ito
M, Soh J, Nishio K, Mitsudomi T, Tsutani Y. Efficacy of Conventional and Novel Tyrosine Kinase
Inhibitors for Uncommon EGFR Mutations-An In Vitro Study. Cells. 2025 Sep 4;14(17):1386.
doi: 10.3390/cells14171386.
Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, Azuma K, Asahina H,
Kisohara A, Kawashima Y, Tanaka H, Kanemaru R, Miyauchi E, Furuya N, Sato H, Nakashima
K, Watanabe S, Sakai K, Nishio K, Takahashi F, Kobayashi K, Maemondo M. A phase II study
of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutationpositive
non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line
osimertinib treatment: NEJ025B study. Eur J Cancer. 2025 Oct 16;229:115693. doi:
10.1016/j.ejca.2025.115693. Epub 2025 Aug 20.
Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K,
Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K,
Yamamoto N, Ohe Y, Okamoto I. Biological impact of chemotherapy during treatment with
EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating
mutations. Lung Cancer. 2025 Oct;208:108756. doi: 10.1016/j.lungcan.2025.108756. Epub 2025
Sep 16.
Saito Y, Adomi S, Sakai K, Antonio De Velasco M, Hashimoto M, Banno E, Hayashi Y, Minami
T, Nishio K, Fujita K. Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter
Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Nonmuscle-
Invasive Bladder Cancer. Cureus. 2025 Aug 24;17(8):e90860. doi: 10.7759/cureus.90860.
eCollection 2025 Aug.
Kawanaka Y, Yonesaka K, Tanizaki J, Maenishi O, Sakai K, Kakimi K, Nishio K, Hayashi H.
Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma
demonstrated a long-term remission to anti PD-1 antibody. Front Oncol. 2025 Sep 10;15:1651248.
doi: 10.3389/fonc.2025.1651248. eCollection 2025.
Sumitomo M, Kotani Y, Murakami K, Abiko K, Sakai K, Otani T, Ueda A, Ukita M, Taga A,
Emoto I, Sekiyama K, Okudate M, Matsubara M, Yamanishi Y, Nishio K, Mandai M, Matsumura
N. Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study. Cancers (Basel). 2025
Sep 19;17(18):3069. doi: 10.3390/cancers17183069.
Kajiyama H, Kashima Y, Otani T, Sakai K, Shiraishi N, Nishio K, Shishido-Hara Y, Ito A,
Minamiguchi S, Matsumura N. Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-
Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation.
Int J Gynecol Pathol. 2025 Oct 2. doi: 10.1097/PGP.0000000000001142. Online ahead of print.
Kurosaki T, Suzuki S, Yonesaka K, Kawanaka Y, Takehara T, Teramura T, Sakai K, Nishio K,
Hayashi H. Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer
Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. Int J
Mol Sci. 2025 Oct 29;26(21):10515. doi: 10.3390/ijms262110515.
13. Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K,
Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa
K. RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With
Untreated EGFR-Mutated Metastatic NSCLC. JTO Clin Res Rep. 2025 Sep 26;6(12):100912.
doi: 10.1016/j.jtocrr.2025.100912. eCollection 2025 Dec.
Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T,
Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E,
Nishio K, Matsumura N. Long-term progression-free survivors ("super responders") to olaparib
maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s). Int J
Clin Oncol. 2026 Feb;31(2):310-318. doi: 10.1007/s10147-025-02942-8. Epub 2025 Dec 22.
Kashima Y, Takaya H, Miyagawa C, Otani T, Sakai K, Nishio K, Matsumura N. A case of
endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma
as a result of TMEM178B-BRAF fusion. Int Cancer Conf J. 2025 Nov 8;15(1):99-102. doi:
10.1007/s13691-025-00823-5. eCollection 2026 Jan.
Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I,
Nishio K. Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse
Large B-Cell Lymphoma. Cancer Med. 2026 Feb;15(2):e71597. doi: 10.1002/cam4.71597.
Iwahashi N, Noguchi T, Sakai K, Yahata T, Nishioka K, Fujino M, Takeda S, Suzuki N, Nishio
K, Ino K. Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy
for cervical cancer. Int J Clin Oncol. 2026 Mar 10. doi: 10.1007/s10147-026-03006-1. Online
ahead of print.
Isomoto K, Haratani K, Tsujikawa T, Tomida S, Makutani Y, Takeda M, Yonesaka K, Tanaka K,
Iwasa T, Sakai K, Nishio K, Ito A, Nakagawa K, Hayashi H. Spatial single-cell proteotyping
reveals immunotherapy-resistant features within the complex tumor microenvironment of
metastatic NSCLC. J Clin Invest. 2026 Mar 10:e195021. doi: 10.1172/JCI195021. Online ahead
of print.
Kanemura H, Takehara T, Maenishi O, Tomida S, Iwawaki N, Kunimasa K, Nakayama T,
Watanabe S, Suzuki S, Sakai K, Azuma K, Kudo K, Nishio K, Nakagawa K, Hayashi H, Teramura
T, Yonesaka K. Constitutive EGFR Activation Induced by PTPRR Downregulation Confers
Resistance to KRAS Inhibitors. Cancer Res Commun. 2026 Apr 1;6(4):728-741. doi:
10.1158/2767-9764.CRC-25-0489.

武内敏秀（ライフサイエンス研究所准教授）

Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M,
Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito
Y, Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset model with
germline transmission that models polyglutamine disease. Dis. Model. Mech. 18(10):
dmm052470 doi:10.1242/dmm.052470
Fujii K, Takeuchi T, Fujino Y, Tanaka N, Fujino N, Takeda A, Minakawa EN, Nagai Y. Oral
administration of arginine suppresses Aβ pathology in animal models of Alzheimer's disease.
Neurochem. Int. 191: 106082 (2025) doi: 10.1016/j.neuint.2025.106082
Takeda A, Takeuchi T, Minakawa EN, Tanaka N, Mochizuki H, Nagai Y. Blood extracellular
vesicles contribute to the exercise-mediated suppression of brain Aβ pathology in the AppNL-GF
knockin mouse model of Alzheimer's disease. Neurochem. Int. 193: 106120 (2026) doi:
10.1016/j.neuint.2026.106120

森樹史（ライフサイエンス研究所助手）

Itokazu M, Takehara T, Toriumi K, Iwawaki N, Mori T, Ondoera Y, Higashimoto Y, Goto K,
Yamada H, Teramura T. Aging-related changes of miR-23b-3p expression in extracellular
vesicles from mesenchymal stromal cells affect TGFBR3 signaling. Scientific Reports
15(1):22186. 2025 Jul.
Takehara T, Tsujimoto T, Ikebuchi F, Miyoshi S, Mori T, Iwawaki N, Shigi K, Houri K, Tago
Y, Teramura T. BNIP3 induced by hypoxia supports the survival of mesenchymal stromal
cells (MSCs) after intravenous cell transplantation. Regen Ther. 2025 Dec;30:224-233
Mori T, Iwawaki N, Shigi K, Takehara T, Takenaka S, Nagai Y, Teramura T. Mesenchymal
stromal cells preserve alveolar macrophages by inducing Sesn2 expression via lactic acid
production in a mouse model of bleomycin-induced lung injury. Cell Transplant. 2025
Dec;34:9636897251397044.

令和7年度

2025年度 ライフサイエンス研究所紀要発刊によせて 研究所長 永井 義隆

令和7年度ライフサイエンス研究所紀要 研究業績

永井 義隆（ライフサイエンス研究所 副所長 兼任 近畿大学 医学部 内科学教室〔脳神経内科部門〕主任教授）

重吉 康史（ライフサイエンス研究所 教授 兼任 近畿大学 医学部 解剖学教室 主任教授）

西尾 和人（ライフサイエンス研究所 ゲノムセンター長 教授 兼任 近畿大学 医学部 ゲノム生物学教室 主任教授）

坂井 和子（ライフサイエンス研究所 ゲノムセンター 准教授 兼任 近畿大学 医学部 ゲノム生物学教室 准教授）

武内 敏秀（ライフサイエンス研究所 准教授）

森 樹史（ライフサイエンス研究所 助手）